US Cardiac Troponin Diagnostics Market, Forecast to 2021

High Prevalence of Heart Disease Propels Market Growth

USD 4,950.00

* Required Fields

USD 4,950.00

PAY BY INVOICE

Be the first to review this product

Cardiac troponins help to diagnose nearly two-thirds of the patients in the diagnosis Acute Coronary Syndrome (ACS) who are missed out by Echocardiogram (ECG). ECG can detect only one-third of the patients with persistent ST-segment Elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS; non-ST segment elevation ACS) who require a conservative Unstable Angina (UA) or early-invasive approach (NSTEMI).In addition to significant pricing challenges, there is growing competition encouraged by the adoption of point-of-care devices at physician offices and hospitals. Although technicians and patients prefer point-of-care devices, physicians and hospitals are still s

Research Scope

The objective of this research is to establish an understanding of the market for cardiac biomarker Troponin used for the diagnosis of acute myocardial infarction. The research covers the revenue generated by the use of cardiac troponin tests for diagnosis of acute myocardial infarction.


Key Issues Addressed

  • What are the key healthcare trends that could impact the global cardiac biomarker diagnostics market?
  • What are the market drivers and restraints that are impacting market growth?
  • What are the unmet needs and opportunities for existing and emerging participants?
  • What are the segment shares of key market participants?
  • How are companies dealing with the challenges in the market space?
  • What are the future trends and how is the forecast scenario of Acute Myocardial infarction (AMI) biomarkers diagnostics in different regions?

Table of Contents

Executive SummaryGlobal Cardiac Troponin Market—Executive Summary US Cardiac Troponins Market—Executive SummaryWestern European Cardiac Troponins Market—Executive SummaryAPAC Cardiac Troponins Market—Executive SummaryScope and SegmentationKey Questions This Study Will AnswerMarket Engineering MeasurementsCardiac Diagnostics Industry OverviewCardiac Biomarkers Diagnostics OverviewExecutive Summary—3 Big PredictionsForecasts and DiscussionMarket Engineering MeasurementsForecast MethodologyRevenue ForecastPercent Revenue Breakdown by Segment—Lab-based Tests Versus POCTRevenue Forecast by SegmentPercent Revenue Forecast by Region Revenue Forecast by RegionPercent of Revenue by RegionRevenue Forecast DiscussionCompetitive EnvironmentMarket ShareMarket Share AnalysisTop CompetitorsTop Competitors (continued)Top Competitors (continued)Top Competitors (continued)Lab-based Tests Segment AnalysisMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionSegment ShareSegment Share AnalysisPOCT Segment AnalysisMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionSegment ShareSegment Share AnalysisRegional Analysis—USExecutive SummaryScope and SegmentationKey Questions This Study Will AnswerMarket Engineering MeasurementsCEO’s PerspectiveKey Companies to WatchMarket OverviewMarket BackgroundMarket Background—Prevalence RateMarket Overview—Testing ProcedureCurrent Trends in US Troponin MarketTroponin Testing LocationsCompetitive PlaybookNew Market OpportunitiesCompetitive StructuresProduct PortfolioProduct Portfolio (continued)Drivers and RestraintsMarket DriversDrivers ExplainedDrivers Explained (continued)Market RestraintsRestraints ExplainedRestraints Explained (continued)Forecasts and DiscussionKey FindingsForecast MethodologyMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionSegment BreakdownRevenue Forecast by SegmentUS Lab-based Test Segment—Pricing Trends and ForecastCompetitive EnvironmentMarket ShareMarket Share AnalysisGrowth OpportunityMajor Growth Opportunities Growth Opportunity Matrix—Key Opportunities and Impact on BusinessesGrowth Opportunity 1—Companion DiagnosticsGrowth Opportunity 2—POCT in Cardiac Biomarker DiagnosticsGrowth Opportunity 3—Integrated and Efficient SystemGrowth Opportunity 4—Digital Health and Diagnostics Inter- convergence ModelStrategic Imperatives for Success and GrowthLab-based Segment AnalysisKey FindingsMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionMarket ShareMarket Share AnalysisPOCT Segment AnalysisKey FindingsMarket Engineering MeasurementsRevenue ForecastRevenue Forecast DiscussionMarket ShareMarket Share AnalysisThe Last WordThe Last Word—3 Big PredictionsLegal DisclaimerAppendixMarket Engineering MethodologyList of Other Companies in Biomarkers Research, Development, and/or ServicesList of Other Companies in Biomarkers Research, Development, and/or Services (continued)List of ExhibitsList of Exhibits (continued)List of Exhibits (continued)List of Exhibits (continued)

Infographic





Keyword1
cardiac troponin
Keyword2

Keyword3
cardiac troponin

Related Research

Release Date : 30-May-18

Region : North America

Release Date : 18-Apr-18

Region : North America

Release Date : 27-Nov-17

Region : Asia Pacific

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.